Merck & Co. Inc. (MRK) News
Filter MRK News Items
MRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRK News Highlights
- For MRK, its 30 day story count is now at 23.
- Over the past 16 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- DOW, DRUG and IMGO are the most mentioned tickers in articles about MRK.
Latest MRK News From Around the Web
Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.
3 High-Yielding Stocks That Are Up 27%-Plus This YearThis year has been one in which many investors have been flocking to safe stocks, including ones that pay dividends. As a result, many normally safe stocks that generate only modest gains have been producing oversized returns for investors. Three stocks that have dwarfed the S&P 500 this year and that are up over 20% and also pay a high rate of dividends include Merck (NYSE: MRK), General Mills (NYSE: GIS), and Chevron (NYSE: CVX). |
4 Defensive Stocks to Prepare Your Portfolio for a RecessionAmid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK are some such stocks. |
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 76%If you want to know who really controls Merck & Co., Inc. ( NYSE:MRK ), then you'll have to look at the makeup of its... |
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?GOSS stock is plunging over 70%. |
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patientsEarly trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday. The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a Phase 3 trial enrolling only those patients by the end of this year, Mirati Chief Executive Officer David Meek told Reuters. The trial will compare the adagrasib combination with the current standard of care, which is chemotherapy plus Keytruda, also known as pembrolizumab. |
The Zacks Analyst Blog Highlights Caterpillar, Merck, UnitedHealth Group and WalmartCaterpillar, Merck, UnitedHealth Group and Walmart are included in this Analyst Blog. |
Merck (NYSE:MRK) Is Increasing Its Dividend To $0.73Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 9th of January to... |
Should Investors Consider These 3 Low-Beta Stocks?During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense. |
In Burkina Faso, a Personal Mission To Make a Difference in One CommunityMerck & Co., Inc. |
Top 4 Blue-Chip Stocks to Enhance Your Portfolio in DecemberWe have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH. |